Anzeige
Meldung des Tages: Diese Goldaktie startet NI-43-101 Ressourcenschätzung – jetzt kann aus der Story Substanz werden

ATyr Pharma Aktie News

Aktie
WKN:  A2PM86 ISIN:  US0021202025 US-Symbol:  ATYR Branche:  Biotechnologie Land:  USA
0,6812 $
-0,0258 $
-3,65%
0,571 € 19:05:09 Uhr
Depot/Watchlist
Marktkapitalisierung *
56,07 Mio. €
Streubesitz
35,14%
KGV
-0,91
Index-Zuordnung
-

ATyr Pharma News

30.11.25 - PR Newswire
ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR
ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR PR Newswire
28.11.25 - PR Newswire
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure PR Newswire
26.11.25 - PR Newswire
ATYR Deadline: ATYR Investors with Losses in Excess of $100K Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
ATYR Deadline: ATYR Investors with Losses in Excess of $100K Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit PR Newswire
26.11.25 - PR Newswire
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
26.11.25 - PR Newswire
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman PR Newswire
25.11.25 - PR Newswire
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman
aTyr Pharma (ATYR) Posts Wider-​Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman PR Newswire
25.11.25 - PR Newswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More PR Newswire
24.11.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of aTyr Pharma, Inc.(ATYR) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of aTyr Pharma, Inc.(ATYR) Shareholders PR Newswire
21.11.25 - PR Newswire
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
21.11.25 - PR Newswire
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma PR Newswire
21.11.25 - PR Newswire
aTyr Pharma, Inc. Class Action: Levi & Korsinsky Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR
aTyr Pharma, Inc. Class Action: Levi & Korsinsky Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR PR Newswire
21.11.25 - PR Newswire
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR PR Newswire
21.11.25 - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
20.11.25 - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit PR Newswire
20.11.25 - PR Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. Lawsuit - ATYR
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. Lawsuit - ATYR PR Newswire
18.11.25 - PR Newswire
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR PR Newswire
18.11.25 - PR Newswire
ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman PR Newswire
18.11.25 - PR Newswire
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Seeking Recovery for Investors - Contact Levi & Korsinsky
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Seeking Recovery for Investors - Contact Levi & Korsinsky PR Newswire
17.11.25 - PR Newswire
Shareholders of aTyr Pharma, Inc. Should Contact The Gross Law Firm Before December 8, 2025 to Discuss Your Rights - ATYR
Shareholders of aTyr Pharma, Inc. Should Contact The Gross Law Firm Before December 8, 2025 to Discuss Your Rights - ATYR PR Newswire
15.11.25 - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit PR Newswire

Newssuche

Videos

newspaper
27.01.26 +1,18%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »